曲妥珠单抗治疗人表皮生长因子受体2阳性晚期胃癌的研究进展  

Research progress in trastuzumab for treating HER2-positive advanced gastric cancer

作　　者：郑宇晨 和水祥[1] ZHENG Yuchen;HE Shuixiang(Department of Internal Medicine,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)

机构地区：[1]西安交通大学第一附属医院内科学系,陕西西安710061

出　　处：《西安交通大学学报（医学版）》2024年第6期879-884,共6页Journal of Xi’an Jiaotong University（Medical Sciences）

摘　　要：胃癌是我国癌症相关死亡的主要原因。靶向药物治疗是胃癌重要的治疗方案之一。人表皮生长因子受体2(HER2)是重要的胃癌治疗靶点,曲妥珠单抗是一种靶向HER2的单克隆抗体,ToGA实验确定曲妥珠单抗联合化疗是HER2阳性晚期胃癌患者的标准治疗方案。本文对ToGA实验及其进展、曲妥珠单抗联合其他化疗药物、曲妥珠单抗联合其他HER2靶向药物、曲妥珠单抗和其他药物偶联物及曲妥珠单抗联合其他靶向位点药物治疗HER2阳性晚期胃癌研究进展进行综述。曲妥珠单抗联合S-1及其他化疗药物表现出了良好的疗效和安全性;帕妥珠单抗和曲妥珠单抗联合化疗未达到主要终点;T-DM1(trastuzumab emtansine)对于HER2阳性晚期胃癌患者在改善总生存期方面没有优势;KN026、T-DXd(trastuzumab deruxtecan)、曲妥珠单抗与派姆单抗联合化疗、贝伐单抗与曲妥珠单抗联合卡培他滨和奥沙利铂是治疗HER2阳性晚期胃癌的最前沿研究进展。Gastric cancer is the leading cause of cancer-related mortality.Targeted drug therapy is one of the most important therapeutic means for gastric cancer.Human epidermal growth factor receptor 2(HER2)is an important therapeutic target for gastric cancer.Trastuzumab is a monoclonal antibody that targets HER2.The ToGA trial has established trastuzumab in combination with chemotherapy as the standard treatment for patients with HER2-positive advanced gastric cancer.This article reviews the progress in ToGA experiment,trastuzumab combined with other chemotherapy drugs,trastuzumab combined with other HER2-targeted drugs,trastuzumab and other drug conjugate,and trastuzumab combined with other targeted drugs in the treatment of HER2-positive advanced gastric cancer.Trastuzumab combined with S-1 and other chemotherapeutic drugs has shown good efficacy and safety;the combination of pertuzumab and trastuzumab did not meet the primary endpoint;trastuzumab emtansine(T-DM1)showed no benefit in improving overall survival in patients with HER2-positive advanced gastric cancer.KN026,trastuzumab deruxtecan(T-DXd),Trastuzumab and Pembrolizumab combined chemotherapy,as well as bevacizumab and trastuzumab combined with capecitabine and oxaliplatin are the most progress research advances in the treatment of HER2-positive advanced gastric cancer.

关 键 词：曲妥珠单抗 人表皮生长因子受体2(HER2) 晚期胃癌 

分 类 号：R573.9[医药卫生—消化系统]